EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 982-989 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 982 - 989
Section Anticorps monoclonaux : quand les cellules de l’immunité s’en mêlent
DOI https://doi.org/10.1051/medsci/2019194
Publié en ligne 6 janvier 2020
  1. Miller RA, Maloney DG, Warnke R, Levy R , Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522. [Google Scholar]
  2. Marshall MJE, Stopforth RJ, Cragg MS , Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunoly. 2017;8:1245. [CrossRef] [Google Scholar]
  3. Cartron G, Watier H, Golay J, Solal-Celigny P , From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–2642. [Google Scholar]
  4. Taylor C, Hershman D , Shah N Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13:5133–5143. [CrossRef] [PubMed] [Google Scholar]
  5. Cartron G, Dacheux L, Salles G, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758. [Google Scholar]
  6. Musolino A, Naldi N , Bortesi B Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–1796. [CrossRef] [PubMed] [Google Scholar]
  7. Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N , Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. 2009;344:1387–1390. [Google Scholar]
  8. Abes R, Dutertre CA, Agnelli L, Teillaud JL , Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target. Rev Clin Immunol. 2009;5:735–747. [CrossRef] [Google Scholar]
  9. Ratner M , Small biotech steers HDAC inhibitor to clinic. Nat biotechnol. 2014;32:853–854. [CrossRef] [PubMed] [Google Scholar]
  10. Mastrangeli R, Palinsky W, Bierau H , Glycoengineered antibodies: towards the next-generation of immunotherapeutics. Glycobiology. 2019;29:199–210. [CrossRef] [PubMed] [Google Scholar]
  11. Mossner E, Brunker P , Moser S Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402. [Google Scholar]
  12. Yu X, Marshall MJE, Cragg MS, Crispin M , Improving antibody-based cancer therapeutics through glycan engineering. BioDrugs. 2017;31:151–166. [CrossRef] [PubMed] [Google Scholar]
  13. Sharman JP, Farber CM, Mahadevan D, et al., Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. 2017;176:412–420. [Google Scholar]
  14. Luo C, Chen S, Xu N, et al., Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Sci Rep. 2017;7:46347. [CrossRef] [PubMed] [Google Scholar]
  15. Wierda WG, Kipps TJ, Mayer J, et al., Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. 2010;28:1749–1755. [Google Scholar]
  16. Michaud HA, Gomard T, Gros L, et al., A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. 2010;6:e1000948. [Google Scholar]
  17. Overdijk MB, Verploegen S, Bogels M , Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7:311–321. [CrossRef] [PubMed] [Google Scholar]
  18. Srivastava RM, Lee SC, Andrade Filho PA, et al., Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–1872. [CrossRef] [PubMed] [Google Scholar]
  19. Borg C, Jalil A , Laderach D NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104:3267–3275. [Google Scholar]
  20. They L, Michaud HA, Becquart O, et al., PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody. Oncoimmunology. 2017;6:e1353857. [CrossRef] [PubMed] [Google Scholar]
  21. Gros L, Dreja H, Fiser AL, et al., Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol. 2005;79:6272–6280. [CrossRef] [PubMed] [Google Scholar]
  22. Gros L, Pelegrin M, Michaud HA, et al., Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol. 2008;82:1339–1349. [CrossRef] [PubMed] [Google Scholar]
  23. Nasser R, Pelegrin M, Michaud HA, et al., Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol. 2010;84:10169–10181. [CrossRef] [PubMed] [Google Scholar]
  24. Abes R, Gelize E, Fridman WH, Teillaud JL , Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116:926–934. [Google Scholar]
  25. DiLillo DJ, Ravetch JV , Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. 2015;161:1035–1045. [Google Scholar]
  26. Park S, Jiang Z , Mortenson ED The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–170. [CrossRef] [PubMed] [Google Scholar]
  27. Mortenson ED, Park S, Jiang Z, et al., Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res. 2013;19:1476–1486. [CrossRef] [PubMed] [Google Scholar]
  28. Nasser R, Pelegrin M , Plays M Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood. 2013;121:1102–1111. [Google Scholar]
  29. Deligne C, Metidji A, Fridman WH, Teillaud JL , Anti-CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. 2015;29:947–957. [Google Scholar]
  30. Ren Z, Guo J, Liao J, et al., CTLA-4 limits anti-CD20-mediated tumor regression. Clin Cancer Res. 2017;23:193–203. [CrossRef] [PubMed] [Google Scholar]
  31. Zhao T, Ren H, Wang X, et al., Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget. 2015;6:27816–27831. [PubMed] [Google Scholar]
  32. Garrido G, Rabasa A, Sanchez B, et al., Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol. 2011;187:4954–4966. [CrossRef] [PubMed] [Google Scholar]
  33. Pozzi C, Cuomo A, Spadoni I, et al., The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat med. 2016;22:624–631. [CrossRef] [PubMed] [Google Scholar]
  34. Singh V, Gupta D , Arora R Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. PloS one. 2014;9:e111113. [CrossRef] [PubMed] [Google Scholar]
  35. Westin JR, Chu F, Zhang M, et al., Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. [CrossRef] [PubMed] [Google Scholar]
  36. Kohrt HE, Colevas AD, Houot R, et al., Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124:2668–2682. [CrossRef] [PubMed] [Google Scholar]
  37. Kohrt HE, Houot R, Weiskopf K, et al., Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122:1066–1075. [CrossRef] [PubMed] [Google Scholar]
  38. Houot R, Kohrt H , CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunol. 2014;3:e941740. [CrossRef] [Google Scholar]
  39. Turaj AH, Hussain K, Cox KL, et al., Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. 2017;32(777–91):e6. [Google Scholar]
  40. Turaj AH, Cox KL , Penfold CA Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8:2278. [CrossRef] [PubMed] [Google Scholar]
  41. Sockolosky JT, Dougan M , Ingram JR Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA. 2016;113:E2646–E2654. [CrossRef] [Google Scholar]
  42. Jones JA, Mato AR, Wierda WG, et al., Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.